CA-UNIPHORE
21.3.2024 14:42:27 CET | Business Wire | Press release
Uniphore, one of the world’s largest AI-native companies, announced a major upgrade to its U-Analyze analytics solution, which builds on the company’s industry-leading multimodal enterprise AI platform to help customers effectively access data and power their AI needs.
This new generative AI-fueled version of U-Analyze directly addresses a growing need among global enterprises to leverage the power of AI and their own data. Drawing from customer conversations across text, voice and video, business leaders can make knowledgeable, timely, data-driven decisions to revolutionize their customers’ experiences as well as agent performance.
This announcement is a deliberate next step following the introduction of Uniphore’s groundbreaking U Capture, an AI-native solution that aids customers’ ability to capture, structure and apply a full suite of multimodal data --- powered by the company’s X-Platform. A key benefit for customers includes the ownership and accessibility of their own data whenever they need it, to drive additional value.
Bolstered by Uniphore’s powerful X-Platform, U-Analyze works seamlessly with U-Capture to analyze conversational data in real time and generate unique AI-driven insights for each enterprise. The insights, along with the automated and manual coaching capabilities, allow enterprises to continuously improve customer experiences and engagement. Ultimately, U-Analyze will help enterprises predict and adapt to customer and market needs.
When you combine the power of the two solutions, the analytics provide timely AI-generated insights that have the potential to dramatically improve customer satisfaction and engagement.
“Analytics will never be the same with Uniphore’s enterprise-grade AI platform transforming the way our customers are able to harness the power and value of data,” said Umesh Sachdev, CEO and Co founder of Uniphore. “This is a significant milestone in Uniphore’s unwavering commitment to our global enterprise customers on their journey to becoming AI-led companies.”
A recent global survey of over 500 contact center leaders sponsored by Uniphore underscored the need for AI-driven insights. For example, nearly 40% of respondents said they lack the data to respond quickly to business decisions or improve their customers’ experiences. Also, 86% said the decisions they make are not predominantly data-driven, reinforcing the massive opportunity for business leaders and enterprises to put their own data to use.
“Enterprise organizations are hungry for better insights – and better conversational analytics solutions. Traditional analytics solutions don’t necessarily include the technologies driving the current wave of innovation in the enterprise – including generative AI and knowledge AI,” said Hayley Sutherland, Research Manager, Conversational AI & Intelligent Knowledge Discovery at IDC. “With these upgrades to U-Analyze, Uniphore is keeping on the cutting edge of such innovations and helping organizations move the needle when it comes to AI-driven actionable insights based on customer interactions, which could have a big impact on business processes and results.”
Uniphore will be at Enterprise Connect at the Gaylord Palms in Orlando, Florida from March 25-28, 2024 at booth 306 in the AI Innovation Zone.
For additional information on the U and Q product lines, please click here.
To stay up to date with the latest commentary, follow our blog, or connect with us on LinkedIn, X, Facebook, or Instagram.
About Uniphore
Uniphore is one of the largest B2B AI-native companies – decades-proven, built-for-scale, and designed for the Enterprise. The company drives business outcomes, across multiple industry verticals, and the largest global deployments. Uniphore infuses AI into every part of the Enterprise that impacts the customer. We deliver the only multimodal AI architecture centered on customers that combines Generative AI, Knowledge AI and Emotion AI and Workflow Automation and a co-pilot to guide you. We understand better than anyone how to capture voice, video, text, and how to analyze all types of data. As AI becomes more powerful, every part of the Enterprise that impacts the customer will be disrupted. We believe the future will run on the connective tissue between people, machines and data: all in service of creating the most human processes and experiences for customers and employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240321078876/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release
SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release
Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a
Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release
Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op
GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release
GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
